Keywords
MS
Remotely supervised transcranial direct current stimulation
RS-tDCS
Categories
How to Cite
Abstract
Background: Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination within the central nervous system, resulting in fatigue, pain, cognitive dysfunction, and motor impairment. Remotely supervised transcranial direct current stimulation (RS‑tDCS) is a noninvasive, low-cost, home-based intervention that modulates neuronal excitability and enhances neural network function, potentially benefiting individuals with MS. This meta-analysis aimed to evaluate the efficacy of RS‑tDCS in MS.
Methods: A systematic search was conducted in PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating RS‑tDCS in MS. The primary outcome was information‑processing speed. Statistical analyses were performed using R software (version 4.5.0) and a random‑effects model to calculate pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane ROB‑2 tool.
Results: Five RCTs, most featuring co-interventions alongside RS-tDCS in both study arms and one specifically targeting MS patients with cannabis use disorder, including 291 participants, were analyzed. Active RS‑tDCS did not significantly improve information‑processing speed (SMD = 0.20; 95% CI: –0.06 to 0.45; P = 0.13, n studies: 4). No significant effects were observed for secondary outcomes.
Conclusion: Evidence from five heterogeneous RCTs, predominantly featuring co-interventions, shows no clear benefit of RS-tDCS for MS cognitive or functional outcomes (very low to low certainty). This highlights substantial uncertainty; larger standalone trials are required.
References
1. Khan G, Hashim MJ. Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections. J Epidemiol Glob Health. 2025: 21 [PMID: 39928193, https://doi.org/10.1007/s44197-025-00353-6]
2. Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024: e37297 [PMID: 38394496, https://doi.org/10.1097/MD.0000000000037297]
3. Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, Di Filippo M, Tur C, Montalban X, Amato MP. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024: 100977 [PMID: 39444703, https://doi.org/10.1016/j.lanepe.2024.100977]
4. Sabatino JJ, Jr., Cree BAC, Hauser SL. New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond. Ann Neurol. 2025: 317 [PMID: 40474602, https://doi.org/10.1002/ana.27270]
5. Cagol A, Schaedelin S, Pretzsch R, Kappos L, Sormani MP, Granziera C. The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis. Lancet Reg Health Eur. 2025: 101476 [PMID: 41080911, https://doi.org/10.1016/j.lanepe.2025.101476]
6. Wu X, Wang S, Xue T, Tan X, Li J, Chen Z, Wang Z. Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials. Front Neurol. 2024: 1295770 [PMID: 38529035, https://doi.org/10.3389/fneur.2024.1295770]
7. Scavone C, Liguori V, Adungba OJ, Cesare DDG, Sullo MG, Andreone V, Sportiello L, Maniscalco GT, Capuano A. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series. Front Neurol. 2024: 1386527 [PMID: 38957352, https://doi.org/10.3389/fneur.2024.1386527]
8. Tramacere I, Virgili G, Perduca V, Lucenteforte E, Benedetti MD, Capobussi M, Castellini G, Frau S, Gonzalez-Lorenzo M, Featherstone R, Filippini G. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2023: CD012186 [PMID: 38032059, https://doi.org/10.1002/14651858.CD012186.pub2]
9. Abboud H, Hill E, Siddiqui J, Serra A, Walter B. Neuromodulation in multiple sclerosis. Mult Scler. 2017: 1663 [PMID: 29115915, https://doi.org/10.1177/1352458517736150]
10. Uygur-Kucukseymen E, Pacheco-Barrios K, Yuksel B, Gonzalez-Mego P, Soysal A, Fregni F. Non-invasive brain stimulation on clinical symptoms in multiple sclerosis patients: A systematic review and meta-analysis. Mult Scler Relat Disord. 2023: 104927 [PMID: 37595371, https://doi.org/10.1016/j.msard.2023.104927]
11. Zhao H, Qiao L, Fan D, Zhang S, Turel O, Li Y, Li J, Xue G, Chen A, He Q. Modulation of Brain Activity with Noninvasive Transcranial Direct Current Stimulation (tDCS): Clinical Applications and Safety Concerns. Front Psychol. 2017: 685 [PMID: 28539894, https://doi.org/10.3389/fpsyg.2017.00685]
12. Hsu WY, Cheng CH, Zanto TP, Gazzaley A, Bove RM. Effects of Transcranial Direct Current Stimulation on Cognition, Mood, Pain, and Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Front Neurol. 2021: 626113 [PMID: 33763014, https://doi.org/10.3389/fneur.2021.626113]
13. Nombela-Cabrera R, Perez-Nombela S, Avendano-Coy J, Comino-Suarez N, Arroyo-Fernandez R, Gomez-Soriano J, Serrano-Munoz D. Effectiveness of transcranial direct current stimulation on balance and gait in patients with multiple sclerosis: systematic review and meta-analysis of randomized clinical trials. J Neuroeng Rehabil. 2023: 142 [PMID: 37875941, https://doi.org/10.1186/s12984-023-01266-w]
14. Palm U, Kumpf U, Behler N, Wulf L, Kirsch B, Worsching J, Keeser D, Hasan A, Padberg F. Home Use, Remotely Supervised, and Remotely Controlled Transcranial Direct Current Stimulation: A Systematic Review of the Available Evidence. Neuromodulation. 2018: 323 [PMID: 28913915, https://doi.org/10.1111/ner.12686]
15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021: n71 [PMID: 33782057, https://doi.org/10.1136/bmj.n71]
16. Cochrane T. Cochrane Handbook for Systematic Reviews of Interventions 2024. Available from: https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current.
17. Clarivate A. EndNote. Preprint at. (n.d.). [Dataset]. 2017.
18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016: 210 [PMID: 27919275, https://doi.org/10.1186/s13643-016-0384-4]
19. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019: l4898 [PMID: 31462531, https://doi.org/10.1136/bmj.l4898]
20. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Jr., Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, Group GW. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008: 1106 [PMID: 18483053, https://doi.org/10.1136/bmj.39500.677199.AE]
21. Prime MUaE. GRADEpro GDT: GRADE-
pro Guideline Development Tool [Software] 2025. Available from: https://www.gradepro.org.
22. Handbook C. Identifying and measuring heterogeneity 2025. Available from: https://handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm.
23. Handbook C. Strategies for addressing heterogeneity 2025. Available from: https://handbook-5-1.cochrane.org/chapter_9/9_5_3_strategies_for_addressing_heterogeneity.htm.
24. Handbook C. Recommendations on testing for
funnel plot asymmetry 2025. Available from: https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm.
25. Charvet L, Goldberg JD, Li X, Best P, Lustberg M, Shaw M, Zhovtis L, Gutman J, Datta A, Bikson M, Pilloni G, Krupp L. Home-based transcranial direct current stimulation paired with cognitive training to reduce fatigue in multiple sclerosis. Sci Rep. 2025: 4551 [PMID: 39915560, https://doi.org/10.1038/s41598-025-88255-2]
26. Charvet LE, Dobbs B, Shaw MT, Bikson M, Datta A, Krupp LB. Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial. Mult Scler. 2018: 1760 [PMID: 28937310, https://doi.org/10.1177/1352458517732842]
27. Pagliari C, Tella SD, Bonanno C, Cacciante L, Cioeta M, De Icco R, Jonsdottir J, Federico S, Franceschini M, Goffredo M, Rainoldi F, Rovaris M, Springhetti I, Calabro RS, Tassorelli C, Rossini PM, Baglio F, for RINTG. Enhancing the effect of rehabilitation on multiple sclerosis: A randomized clinical trial investigating the impact of remotely-supervised transcranial direct current stimulation and virtual reality telerehabilitation training. Mult Scler Relat Disord. 2025: 106256 [PMID: 39799756, https://doi.org/10.1016/j.msard.2024.106256]
28. Pilloni G, Lustberg M, Malik M, Feinberg C, Datta A, Bikson M, Gutman J, Krupp L, Charvet L. Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial. Mult Scler. 2024: 1490 [PMID: 39268655, https://doi.org/10.1177/13524585241275013]
29. Pilloni G, Pehel S, Ko T, Sammarco C, Charlson RE, Hanlon CA, Charvet L. Telehealth tDCS to reduce cannabis use: A pilot RCT in multiple sclerosis as a framework for generalized use. Drug Alcohol Depend. 2025: 112706 [PMID: 40378662, https://doi.org/10.1016/j.drugalcdep.2025.112706]
30. Shaw M, Pilloni G, Charvet L. Delivering Transcranial Direct Current Stimulation Away From Clinic: Remotely Supervised tDCS. Mil Med. 2020: 319 [PMID: 32074357, https://doi.org/10.1093/milmed/usz348]
31. Bjekic J, Zivanovic M, Stankovic M, Paunovic D, Konstantinovic U, Filipovic SR. The subjective experience of transcranial electrical stimulation: a within-subject comparison of tolerability and side effects between tDCS, tACS, and otDCS. Front Hum Neurosci. 2024: 1468538 [PMID: 39507062, https://doi.org/10.3389/fnhum.2024.1468538]
32. Kasschau M, Reisner J, Sherman K, Bikson M, Datta A, Charvet LE. Transcranial Direct Current Stimulation Is Feasible for Remotely Supervised Home Delivery in Multiple Sclerosis. Neuromodulation. 2016: 824 [PMID: 27089545, https://doi.org/10.1111/ner.12430]
33. Gough N, Brkan L, Subramaniam P, Chiuccariello L, De Petrillo A, Mulsant BH, Bowie CR, Rajji TK. Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review. PLoS One. 2020: e0223029 [PMID: 32092069, https://doi.org/10.1371/journal.pone.0223029]
34. Charvet LE, Kasschau M, Datta A, Knotkova H, Stevens MC, Alonzo A, Loo C, Krull KR, Bikson M. Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols. Front Syst Neurosci. 2015: 26 [PMID: 25852494, https://doi.org/10.3389/fnsys.2015.00026]
35. Cuypers K, Leenus DJ, Van Wijmeersch B, Thijs H, Levin O, Swinnen SP, Meesen RL. Anodal tDCS increases corticospinal output and projection strength in multiple sclerosis. Neurosci Lett. 2013: 151 [PMID: 24036466, https://doi.org/10.1016/j.neulet.2013.09.004]
36. Tapsell LC, Pinto MD, Vallence AM, Whife C, Perez Armendariz ML, Senger S, Andringa-Bate J, Hince D, Murphy MC. What are the optimal transcranial direct current stimulation parameters and design elements to modulate corticospinal excitability? A systematic review and longitudinal meta-analysis. Neurol Res Pract. 2025: 86 [PMID: 41219988, https://doi.org/10.1186/s42466-025-00449-1]
37. Pilloni G, Vogel-Eyny A, Lustberg M, Best P, Malik M, Walton-Masters L, George A, Mirza I, Zhovtis L, Datta A, Bikson M, Krupp L, Charvet L. Tolerability and feasibility of at-home remotely supervised transcranial direct current stimulation (RS-tDCS): Single-center evidence from 6,779 sessions. Brain Stimul. 2022: 707 [PMID: 35470019, https://doi.org/10.1016/j.brs.2022.04.014]
38. Kang J, Lee H, Yu S, Lee M, Kim HJ, Kwon R, Kim S, Fond G, Boyer L, Rahmati M, Koyanagi A, Smith L, Nehs CJ, Kim MS, Sanchez GFL, Dragioti E, Kim T, Yon DK. Effects and safety of transcranial direct current stimulation on multiple health outcomes: an umbrella review of randomized clinical trials. Mol Psychiatry. 2024: 3789 [PMID: 38816583, https://doi.org/10.1038/s41380-024-02624-3]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Omar Khaled Abdelsalam, Mousa Almasalma, Ali Nagy Shelbaya, Ahmed Raja Albishti, Mohamed H. Khalil, Hamza Khelifa, Ahmed Abdelsalam, Asmaa Zakria Alnajjar